About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

RECRUITINGPhase 4NCT07478484

Different Administration Regimens of CAZ-AVI in Combination With ATM for the Treatment of CR-GNB

Metallo-β-lactamase-producing carbapenem-resistant Gram-negative bacteria (MBL-CR-GNB), due to their capacity to hydrolyze almost all β-lactam antibiotics, have become a critical global threat in anti...

Lead sponsor: Jing Zhou•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Jing Zhou

Age

18 - 100 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•1. Patients diagnosed with complicated intra-abdominal infection (cIAI), hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), complicated urinary tract infection (cUTI), or bloodstream infection (BSI);
•2. Patients with confirmed infections caused by metallo-β-lactamase-producing carbapenem-resistant Gram-negative bacteria (MBL-CR-GNB), as determined by genotypic testing using next-generation sequencing (NGS) or carbapenem resistance gene testing;
•3. Patients receiving treatment with ceftazidime-avibactam in combination with aztreonam.

Exclusion Criteria

•1. Patients aged under 18 years;
•2. Patients with known hypersensitivity to ceftazidime, avibactam, aztreonam, or any of the excipients; or those with a history of severe hypersensitivity reactions (e.g., anaphylactic shock, severe skin reactions) to any other β-lactam antibacterial agents (such as penicillins, monobactams, or carbapenems);
•3. Pregnant or breastfeeding women;
•4. Patients unable to comprehend or comply with the study protocol;
•5. Any other condition which, in the investigator's discretion, makes the patient unsuitable for participation in the trial.

Related studies

RECRUITINGPhase 2

Clinical Trial to Study the Efficacy and Safety of Fluorothiazinone (N.F. Gamaleya NRCEM) in Prophylaxis of Nosocomial Bacterial Infections With Participation of Patients on MV

NCT06135350 · Gram Negative Pneumonia, Gram-Negative Bacterial Infections, and more

COMPLETEDPhase 2

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Neonates and Infants

NCT06086626 · Gram-Negative Bacterial Infections

COMPLETEDPhase 2

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of Cefiderocol in Hospitalized Pediatric Participants

NCT04335539 · Gram-negative Bacterial Infections, Bloodstream Infections (BSI), and more

COMPLETEDPhase 2/3

Safety, Tolerability, Efficacy and Pharmacokinetics of Imipenem/Cilastatin/Relebactam (MK-7655A) in Pediatric Participants With Gram-negative Bacterial Infection (MK-7655A-021)

NCT03969901 · Suspected or Documented Gram-negative Bacterial Infection

COMPLETEDPhase 2/3

Pharmacokinetics of Intraperitoneal and Intravenous Meropenem, Ampicillin, Aztreonam and Ciprofloxacin in Automated Peritoneal Dialysis Patients Without Peritonitis

NCT07113587 · Peritoneal Dialysis-associated Peritonitis, Peritoneal Dialysis (PD), and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: March 17, 2026Terms

Trial snapshot

StatusRECRUITING

PhasePHASE4

Enrollment144

Start dateMar 2026

Last updatedMar 17, 2026

Condition

Ceftazidime-avibactam Aztreonam Gram-negative Bacterial Infection Metallo-β-lactamase-producing Carbapenem-resistant

Locations shown

Jing Zhou

Nanjin, Jiangsu

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 17, 2026Data synced to Clareo: May 17, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions